Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 5 | Journal of Translational Medicine

Fig. 5

From: Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL

Fig. 5

Effects of single drug treatment or different combinations of IM, NL and RUX on the engraftment of human Ph+ALL cells in the anti-CD122-conditioned NOD/SCID recipients transplanted with LPCs from Ph+ALL patients. a Experimental design for the in vivo experiments. LPCs sorted from newly diagnosed Ph+ALL patients (N = 6) were transplanted by IBMI into 5-week-old, sub-lethally irradiated (2.1 Gy of total body irradiation from a 60Co source) and anti-CD122-conditioned NOD/SCID mice. From +14 days post-transplantation, the recipient mice were randomly administered with vehicle (10% NMP-90% PEG 300), IM (100 mg/kg/day), NL (75 mg/kg/day), RUX (30 mg/kg/day), IM (100 mg/kg/day) combined with RUX (30 mg/kg/day), or NL (75 mg/kg/day) combined with RUX (30 mg/kg/day) via oral gavage for 14 days. b The engraftment levels of human Ph+ALL CD45+ cells in the BMs and spleens of mice under different treatment conditions were analyzed by flow cytometry at 8 weeks (N = 6 patients, N = 3 mice per patient per treatment group) and c at 12 weeks post-transplant (N = 6 patients, N = 3 mice per patient per treatment group) or until the mice were moribund

Back to article page